II. Indications
- Atrophic Vaginitis in Menopause
- Postmenopausal Dyspareunia
III. Precautions
- Higher dose Topical Estrogens require concurrent Progesterone if Uterus intact (risk of Endometrial Hyperplasia)
- Lower dose Topical Estrogens do not require systemic Progesterone (in intact Uterus) if used <1 year
- Obtain Transvaginal Ultrasound (endometrial stripe) and Endometrial Biopsy if vaginal spotting or bleeding
- Some guidelines allow use of low dose Topical Estrogens indefinately
- No consistent guidelines as whether low dose agents require Progesterone with prolonged use >1 year
- Krause (2009) J Pelvic Med Surg 15(3): 105–14 [PubMed]
IV. Preparations: High Dose Topical Estrogens
- Indicated for vasomotor symptoms AND Genitourinary Syndrome of Menopause (Vaginal Atrophy)
- Requires concurrent progesteron use
-
Estradiol acetate vaginal ring (FemRing)
- Placed in vagina and replaced every 90 days
- Available as 0.05 and 0.1 mg/day rings
- Requires opposing Progesterone if Uterus intact (risk of Endometrial Hyperplasia)
V. Preparations: Low Dose Topical Estrogens
- Indicated for Genitourinary Syndrome of Menopause
- Background
- Minimal Estrogen absorption and may safely be used at any age (even with Cardiovascular Risks)
- Avoid in Breast Cancer Survivors unless allowed by oncology in patients with refractory genitourinary symptoms
- Estradiol Vaginal Ring (Estring)
- Placed in vagina and replaced every 90 days
- Available as 2 mg rings (releases 7.5 mcg Estradiol per day)
- Estradiol Vaginal Tablet (Vagifem, Yuvafem)
- Initial: One tablet intravaginally daily for 2 weeks
- Later: One tablet intravaginally twice weekly
- Available in 10 mcg (typical use) and 25 mcg applicators
- May be safe at low dose, low frequency use despite history of Breast Cancer
- Low systemic absorption at low dose
- Requires Informed Consent regarding potential risks and lack of safety studies following Breast Cancer
- Pruthi (2012) Mayo POIM Conference, Rochester
-
Estradiol vaginal soft gel (Imvexxy)
- Released in 2018 at $180/month or twice the cost of generic vaginal creams
- Available as 4 mcg dose (menopausal Dyspareunia) and a 10 mcg dose
- Start with one vaginal insert once daily for 2 weeks
- Next insert once twice weekly
- (2018) Presc Lett 25(9): 53
- Estrogen Cream (Premarin or Estrace Creams)
- Premarin (Conjugated Estrogen 0.625 mg per 1 g cream)
- Apply 0.5 g (up to 2 g) daily for 21 of every 28 days OR
- Apply 0.5 g applied intravaginally twice weekly
- Estrace (Estradiol)
- Concentration: 0.1 mg Estradiol per 1 g cream
- Apply 2 to 4 g intravaginally daily for 2 weeks, then reduce to 0.5 to 1 g twice weekly
- Premarin (Conjugated Estrogen 0.625 mg per 1 g cream)
- Prasterone or DHEA (Intrarosa)
VI. References
Images: Related links to external sites (from Bing)
Related Studies
femring (on 1/1/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
FEMRING 0.05 MG/DAY VAG RING | $664.72 each | |
FEMRING 0.10 MG/DAY VAG RING | $712.28 each | |
estring (on 7/12/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ESTRING 2 MG VAGINAL RING | $507.72 each | |
ESTRING 7.5 MCG/DAY (2 MG) RING | $507.72 each | |
vagifem (on 2/23/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
VAGIFEM 10 MCG VAGINAL TAB | Generic | $7.56 each |
intrarosa (on 1/1/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
INTRAROSA 6.5 MG VAG INSERT | $8.74 each |